We are live on
!
Find out more
Galectin Therapeutics
GALT
GALT
84 hedge funds and large institutions have $43.9M invested in Galectin Therapeutics in 2025 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 21 increasing their positions, 26 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
98% more capital invested
Capital invested by funds: $22.2M → $43.9M (+$21.7M)
76% more call options, than puts
Call options by funds: $1.28M | Put options by funds: $728K
0.51% less ownership
Funds ownership: 16.61% → 16.1% (-0.51%)
6% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 16
2% less funds holding
Funds holding: 86 → 84 (-2)
19% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 26
Holders
84
Holders Change
-2
Holders Change %
-2.33%
% of All Funds
1.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
21
Reduced
26
Closed
16
Calls
$1.28M
Puts
$728K
Net Calls
+$555K
Net Calls Change
+$1.25M
Top Buyers
Top Sellers
| 1 |
Jane Street
New York
|
-$2.76M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$513K |
| 3 |
BlackRock
New York
|
-$354K |
| 4 |
SIA
Soltis Investment Advisors
St. George,
Utah
|
-$297K |
| 5 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
-$237K |
